Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Lipocine Price Performance Shares of NASDAQ LPCN opened at $4.92 on Friday. The stock has a market capitalization […]

Leave a Reply

Your email address will not be published.

Previous post Bright Horizons Family Solutions (NYSE:BFAM) Price Target Raised to $119.00 at JPMorgan Chase & Co.
Next post Scale AI Establishes First International HQ in UK